Pilar Garcia-Vello

Dr. Pilar Garcia-Vello

Federico II University of Naples
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2023 in Trends in Food Science & Technology
Verified
Journal Article
Open access
ICIrene Cattaneo
Irene Cattaneo
MAMaria Chiara Astuto
Maria Chiara Astuto
MBMarco Binaglia
Marco Binaglia
YDYann Devos
Yann Devos
JDJean Lou C.M. Dorne
Jean Lou C.M. Dorne
ATAndrea Terron
Andrea Terron

1 February 2022 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
Pilar Garcia-VelloPilar Garcia-Vello
Pilar Garcia-Vello
Flaviana Di LorenzoFlaviana Di Lorenzo
Flaviana Di Lorenzo
DZDaniele Zucchetta
Daniele Zucchetta
AZAlla Zamyatina
Alla Zamyatina
Cristina De CastroCristina De Castro
Cristina De Castro
Antonio MolinaroAntonio Molinaro
Antonio Molinaro

27 September 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
Pilar Garcia-VelloPilar Garcia-Vello
Pilar Garcia-Vello
HTHanne L. P. Tytgat
Hanne L. P. Tytgat
JEJanneke Elzinga
Janneke Elzinga
MHMatthias Van Hul
Matthias Van Hul
HPHubert Plovier
Hubert Plovier
WVWillem M De Vos
Willem M De Vos
The cell-envelope of Gram-negative bacteria contains endotoxic lipopolysaccharides (LPS) that are recognized by the innate immune system via Toll-Like Receptors (TLRs). The intestinal mucosal symbiont Akkermansia muciniphila is known to confer beneficial effects on the host and has a Gram-negative architecture. Here we show that A. muciniphila LPS lacks the O-polysaccharide repeating unit, with the resulting lipooligosaccharide (LOS) having unprecedented structural and signaling properties. The LOS consists of a complex glycan chain bearing two distinct undeca- and hexadecasaccharide units each containing three 2-keto-3-deoxy-D-manno-octulosonic acid (Kdo) residues. The lipid A moiety appears as a mixture of differently phosphorylated and acylated species and carries either linear or branched acyl moieties. Peritoneal injection of the LOS in mice increased higher gene expression of liver TLR2 than TLR4 (100-fold) and induced high IL-10 gene expression. A. muciniphila LOS was found to signal both through TLR4 and TLR2, whereas lipid A only induced TLR2 in a human cell line. We propose that the unique structure of the A. muciniphila LOS allows interaction with TLR2, thus generating an anti-inflammatory response as to compensate for the canonical inflammatory signaling associated with LOS and TLR4, rationalizing its beneficial host interaction.

1 October 2021 in Frontiers in Immunology
Verified
Journal Article
Open access
DLDimitra Lamprinaki
Dimitra Lamprinaki
Pilar Garcia-VelloPilar Garcia-Vello
Pilar Garcia-Vello
RMRoberta Marchetti
Roberta Marchetti
CHCharlotte Hellmich
Charlotte Hellmich
KMKelli A. McCord
Kelli A. McCord
NJNathalie Juge
Nathalie Juge
Fusobacterium nucleatum is involved in the development of colorectal cancer (CRC) through innate immune cell modulation. However, the receptors of the interaction between F. nucleatum ssp. and immune cells remain largely undetermined. Here, we showed that F. nucleatum ssp. animalis interacts with Siglecs (sialic acid–binding immunoglobulin-like lectins) expressed on innate immune cells with highest binding to Siglec-7. Binding to Siglec-7 was also observed using F. nucleatum-derived outer membrane vesicles (OMVs) and lipopolysaccharide (LPS). F. nucleatum and its derived OMVs or LPS induced a pro-inflammatory profile in human monocyte-derived dendritic cells (moDCs) and a tumour associated profile in human monocyte-derived macrophages (moMϕs). Siglec-7 silencing in moDCs or CRISPR-cas9 Siglec-7-depletion of U-937 macrophage cells altered F. nucleatum induced cytokine but not marker expression. The molecular interaction between Siglec-7 and the LPS O-antigen purified from F. nucleatum ssp. animalis was further characterised by saturation transfer difference (STD) NMR spectroscopy, revealing novel ligands for Siglec-7. Together, these data support a new role for Siglec-7 in mediating immune modulation by F. nucleatum strains and their OMVs through recognition of LPS on the bacterial cell surface. This opens a new dimension in our understanding of how F. nucleatum promotes CRC progression through the generation of a pro-inflammatory environment and provides a molecular lead for the development of novel cancer therapeutic approaches targeting F. nucleatum-Siglec-7 interaction.

1 April 2020 in Carbohydrate Polymers
Verified
Journal Article
Open access
Pilar Garcia-VelloPilar Garcia-Vello
Pilar Garcia-Vello
GSGarima Sharma
Garima Sharma
ISImmacolata Speciale
Immacolata Speciale
AMAntonio Molinaro
Antonio Molinaro
SISin-Hyeog Im
Sin-Hyeog Im
Cristina De CastroCristina De Castro
Cristina De Castro
The capsular material from Lactobacillus plantarum IMB19, an isolate from fermented vegetables, has been analyzed and our results demonstrate that most of the coat of this bacterium consists of glycerol- and ribitol-type teichoic acids, further decorated with other substituents (α-glucose and alanine), and of a capsular polysaccharide (CPS) with a linear nonasaccharide repeating unit, rich in rhamnose, interconnected to the next via a phosphodiester bridge. Stimulation of immune cells with the total capsular material resulted in the enhancement of immunostimulatory (IFNγ, TNF-α, IL-6 and IL-12) or immuno-regulatory (IL-10) cytokines in an in vitro splenocyte culture system. The capsular polysaccharide, and not the teichoic acids mixture, was responsible for the IFNγ production. Indeed, a significant increase of IFNγ along with other inflammatory cytokines, and a dose response in IFNγ expression with an EC50 of 3.16 μM was found for CPS, disclosing that this polysaccharide is a potent immunostimulatory molecule.

1 December 2020 in Drug Discovery Today: Technologies
Verified
Journal Article
Open access
Pilar Garcia-VelloPilar Garcia-Vello
Pilar Garcia-Vello
ISImmacolata Speciale
Immacolata Speciale
FCFabrizio Chiodo
Fabrizio Chiodo
Antonio MolinaroAntonio Molinaro
Antonio Molinaro
Cristina De CastroCristina De Castro
Cristina De Castro
Carbohydrate adjuvants are safe and biocompatible compounds usable as sustained delivery systems and stimulants of ongoing humoral and cellular immune responses, being especially suitable for the development of vaccines against intracellular pathogens where alum is useless. The development of new adjuvants is difficult and expensive, however, in the last two years, seven new carbohydrate-based adjuvants have been patented, also there are twelve ongoing clinical trials of vaccines that contain carbohydrate-based adjuvants, as well as numerous publications on their mechanism of action and safety. More research is necessary to improve the existent adjuvants and develop innovative ones.